Novartis biological drug Ilaris approved in EU to treat children and adults with CAPS, a rare debilitating auto-inflammatory disease

Links shared publicly online about this topic.

1,645
total visits

Novartis biological drug Ilaris approved in EU to treat children and adults with CAPS, a rare debilitating auto-inflammatory disease

Basel, October 28, 2009 - The new biological medicine Ilaris (canakinumab) has been approved in the European Union (EU) to treat adults and children as young as four years old with cryopyrin-associated periodic syndrome (CAPS), a rare life-long auto-inflammatory disease with debilitating symptoms and few treatment options[1],[2],[3].

View full resource at novartis.com

Tags: Disease and Condition, Drug, Children's Health, Novartis